Key result
Transcoronary Wharton jelly stem cells linked to ~16% absolute LVEF improvement in one AMI patient.
Case Report (n=1)
No
The paper describes a multi-modality imaging framework for a randomized controlled trial evaluating Wharton jelly mesenchymal stem cells for myocardial repair in acute myocardial infarction.
Multi-modality imaging framework enables future stem cell RCTs in AMI; leaves open clinical efficacy of Wharton jelly MSCs.
ENWEndNote BIBJabRef, Mendeley RISPapers, Reference Manager, RefWorks, Zotero AMA Drabik L, Mazurek A, Czyż Ł, et al. Multi-modality imaging in the CIRCULATE-AMI pilot study cohort: a framework for an imaging-based randomized controlled trial of Wharton jelly mesenchymal stem cell use to stimulate myocardial repair/regeneration. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej. 2023. doi:10.5114/aic.2023.124361. APA Drabik, L., Mazurek, A., Czyż, Ł., Tekieli, Ł., Szot, W., & Kwiecień, E. et al. (2023). Multi-modality imaging in the CIRCULATE-AMI pilot study cohort: a framework for an imaging-based randomized controlled trial of Wharton jelly mesenchymal stem cell use to stimulate myocardial repair/regeneration. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej. https://doi.org/10.5114/aic.2023.124361 Chicago Drabik, Leszek, Adam Mazurek, Łukasz Czyż, Łukasz Tekieli, Wojciech Szot, Ewa Kwiecień, and Robert Paweł Banyś et al. 2023. "Multi-modality imaging in the CIRCULATE-AMI pilot study cohort: a framework for an imaging-based randomized controlled trial of Wharton jelly mesenchymal stem cell use to stimulate myocardial repair/regeneration". Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej. doi:10.5114/aic.2023.124361. Harvard Drabik, L., Mazurek, A., Czyż, Ł., Tekieli, Ł., Szot, W., Kwiecień, E., Banyś, R., Urbańczyk-Zawadzka, M., Borkowska, E., Kozynacka, A., Skubera, M., Brzyszczyk-Marzec, M., Kostkiewicz, M., Majka, M., Podolec, P., and Musiałek, P. (2023). Multi-modality imaging in the CIRCULATE-AMI pilot study cohort: a framework for an imaging-based randomized controlled trial of Wharton jelly mesenchymal stem cell use to stimulate myocardial repair/regeneration. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej. https://doi.org/10.5114/aic.2023.124361 MLA Drabik, Leszek et al. "Multi-modality imaging in the CIRCULATE-AMI pilot study cohort: a framework for an imaging-based randomized controlled trial of Wharton jelly mesenchymal stem cell use to stimulate myocardial repair/regeneration." Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej, 2023. doi:10.5114/aic.2023.124361. Vancouver Drabik L, Mazurek A, Czyż Ł, Tekieli Ł, Szot W, Kwiecień E et al. Multi-modality imaging in the CIRCULATE-AMI pilot study cohort: a framework for an imaging-based randomized controlled trial of Wharton jelly mesenchymal stem cell use to stimulate myocardial repair/regeneration. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej. 2023. doi:10.5114/aic.2023.124361.
No takes yet. Share an insight, caveat, or question.
Drabik et al. (2022) conducted a case report in Acute myocardial infarction (n=1). Wharton jelly mesenchymal stem cells (WJMSC) was evaluated on Change in left ventricular ejection fraction (LVEF) and perfusion deficit at 6 months. Transcoronary administration of 30 million Wharton jelly mesenchymal stem cells in a patient with acute myocardial infarction was associated with an absolute LVEF improvement of 15-18% and a 7% absolute reduction in perfusion deficit at 6 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: